Current best practices and rationalistic perspectives in causation-based prevention, early detection and multidisciplinary treatment of breast and gastric cancer

PAST ISSUES
Volume 10
Number 1

Eribulin, epigenome and miRNAs cancer therapeutics targets - Beyond?
1-18
10.2122/gbc.2011.0147
To test my genome?
19 -24
10.2122/gbc.2011.0148
Cetuximab: Explaining resistance and disappointing new results
25-29
10.2122/gbc.2011.0146
Multimodal treatment including trastuzumab for gastroesophageal junction cancer: Controversy, and individualized decision.
30-35
10.2122/gbc.2011.0151
Challenges in reaching true robust novel breast cancer markers
36-42
10.2122/gbc.2011.0150
Breast cancer: New key phase 3 trials data on sentinel node, recurrence biopsy and bevacizumab
43-46
10.2122/gbc.2011.0149
Family history and BRCA testing: Challenges in deciding between risk-reducing surgery and surveillance including MRI
47-52
10.2122/gbc.2011.0153
MicroRNAs: A new class of therapeutic targets in cancer
53-58
10.2122/gbc.2011.0152
 

Online ISSN : 1109 - 7647
   Print ISSN : 1109 - 7655

We subscribe to the HONcode principles of the HON Foundation. Click to verify. We subscribe to the HONcode principles. Verify here.
please, read our policy about privacy and confidentiality of information and transparency of sponsorship

last update: 23 March 2011